Sage Therapeutics has rejected the unsolicited acquisition offer it received earlier this month from longtime partner Biogen ...
After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on ...
Sage Therapeutics said on Monday that its board has unanimously rejected the takeover offer it received from Biogen. The ...
Biogen’s effort to buy Sage against the board’s wishes and a long-time effort by investor Alcorn to scuttle Aurion’s IPO ...
Following a lawsuit filed last week, Sage has officially rejected Biogen’s unsolicited buyout offer, which valued the ...
11d
Hosted on MSNBiogen Rises On FDA Nod for Alzheimer's Drug Dosing Regimen, But Sage Deal Fallout Irks RetailBiogen Inc. shares climbed 1.7% on Monday afternoon, reaching a nearly two-week high, as positive regulatory news countered ...
10d
GlobalData on MSNSage rejects Biogen’s $469m takeover bidSage’s board of directors said that the proposal “significantly undervalues” the company and is not in the best interest of ...
Since then, Biogen decided to opt out of their partnership on essential tremor candidate SAGE-324 after disappointing results ...
Sage’s board of directors said Biogen’s offer “undervalues” the company, but will explore other strategic alternatives to ...
Sage Therapeutics announced its boards unanimous rejection of Biogens $469 million acquisition offer, stating the proposal ...
Sage Therapeutics rejected a takeover offer from Biogen ( BIIB) and said it started a process to review its strategic ...
Sage Therapeutics (SAGE) announced that its board of directors has initiated a process to explore strategic alternatives for the company. The ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results